Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open‐label safety study

OBJECTIVE: During the development of cenobamate, an antiseizure medication (ASM) for focal seizures, three cases of drug reaction with eosinophilia and systemic symptoms (DRESS) occurred. To mitigate the rate of DRESS, a start‐low, go‐slow approach was studied in an ongoing, open‐label, multicenter...

Descripción completa

Detalles Bibliográficos
Autores principales: Sperling, Michael R., Klein, Pavel, Aboumatar, Sami, Gelfand, Michael, Halford, Jonathan J., Krauss, Gregory L., Rosenfeld, William E., Vossler, David G., Wechsler, Robert, Borchert, Leona, Kamin, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Full‐length Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317552/
https://www.ncbi.nlm.nih.gov/pubmed/32396252
http://dx.doi.org/10.1111/epi.16525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317552/
https://www.ncbi.nlm.nih.gov/pubmed/32396252
http://dx.doi.org/10.1111/epi.16525

Ejemplares similares